Browsing Category
Featured Articles
Pfizer Granted FDA Breakthrough Therapy Designation for RSV Vaccine Candidate
Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug…
Read More...
Read More...
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to…
Read More...
Read More...
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport…
Eli Lilly and Company announced the launch of the Lilly Institute for Genetic Medicine and an investment of approximately $700 million to establish a state-of-the-art facility at a new…
Read More...
Read More...
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active…
Read More...
Read More...
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric…
Pfizer Inc. and OPKO Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA)…
Read More...
Read More...
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for…
Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, announced they have…
Read More...
Read More...
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop…
Century Therapeutics and Bristol Myers Squibb announced today a research collaboration and license agreement (the “agreement”) to develop and commercialize up to four induced…
Read More...
Read More...
Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration…
Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and…
Read More...
Read More...
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Novo Nordisk announced that the acquisition of Dicerna Pharmaceuticals, Inc. announced on 18 November 2021, has been completed.
Following the expiration of Novo Nordisk’s cash tender…
Read More...
Read More...
Merck Collaborates with Innovative Biotech to Support Establishment of First Vaccine Production…
Merck, a leading science and technology company, announced that it has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the…
Read More...
Read More...
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. and Arena Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company…
Read More...
Read More...
Thermo Fisher Scientific Completes Acquisition of PPD
Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. for $17.4 billion.
"We are very excited to officially welcome our PPD colleagues to Thermo…
Read More...
Read More...
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
Sanofi announced it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin…
Read More...
Read More...
Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform
Novo Nordisk announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi)…
Read More...
Read More...
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a…
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced US government contracts totalling approximately $1 billion (USD) to purchase sotrovimab, an investigational monoclonal antibody…
Read More...
Read More...
Pfizer To Provide U.S. Government With 10 Million Treatment Courses Of Investigational Oral…
Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332;…
Read More...
Read More...
Amgen Successfully Completes Acquisition Of Teneobio, Inc.
Amgen announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective as of Oct. 19, 2021, Amgen has acquired all outstanding…
Read More...
Read More...
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
Boehringer Ingelheim inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria. With an investment volume of more than…
Read More...
Read More...
Sanofi to acquire Kadmon to further strengthen growth of transplant business
Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease…
Read More...
Read More...
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA…
Read More...
Read More...